CRISPR Therapeutics AG (CRSP) Other Accumulated Expenses (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Other Accumulated Expenses data on file, last reported at $13.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $13.1 million; the trailing twelve-month figure through Mar 2026 stood at $13.1 million (changed N/A YoY), and the FY2025 full-year result was $13.1 million, up 25.88% from the prior year.
• Other Accumulated Expenses was little changed at $13.1 million in Q1 2026, from $13.1 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $13.1 million in Q4 2025 to a low of $20000.0 in Q1 2023.
• A 5-year average of $3.7 million and a median of $1.2 million in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses sank 92.59% in 2023 and jumped 24020.0% in 2024, its largest moves.
• Tracing CRSP's Other Accumulated Expenses over 5 years: stood at $1.2 million in 2022, then soared by 341.67% to $5.1 million in 2023, then jumped by 102.63% to $10.4 million in 2024, then rose by 25.88% to $13.1 million in 2025, then changed by 0.0% to $13.1 million in 2026.
• Business Quant data shows CRSP's Other Accumulated Expenses at $13.1 million in Q1 2026, $13.1 million in Q4 2025, and $604000.0 in Q2 2025.